In glioblastoma cells, paeoniflorin treatment can suppress tumor cell migration and invasion and actin cytoskeleton rearrangement by inhibiting c-Met-mediated RhoA/ROCK signaling and EMT (Wang et al., 2018d; Yu et al., 2019a), deactivating STAT3 signaling (Nie et al., 2015), or increasing miR-16 expression (Li et al., 2015). Here, MET is linked to glioblastoma.